开云app官网登录入口网页版-官方正版

#MCL#

4篇内容 | 972人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2207477, encodeId=cdfd220e477e4, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a> <a href='/topic/show?id=75948599ec3' target=_blank style='color:#2F92EE;'>#自体干细胞移植#</a> <a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a> <a href='/topic/show?id=c79411380f9' target=_blank style='color:#2F92EE;'>#MCL#</a>, objectTitle=Nat. Rev. Clin. Oncol | 在一线治疗中添加伊布替尼可以改善符合移植资格的MCL患者的预后, objectType=article, longId=827778, objectId=a18082e778f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240527/1716820968077_6145188.png, objectUrl=/article/show_article.do?id=a18082e778f4, replyNumber=0, likeNumber=71, createdTime=2024-05-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a18082e778f4, moduleTitle=Nat. Rev. Clin. Oncol | 在一线治疗中添加伊布替尼可以改善符合移植资格的MCL患者的预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a18082e778f4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2201882, encodeId=7d2122018822a, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=c79411380f9' target=_blank style='color:#2F92EE;'>#MCL#</a>, objectTitle=【Hematol Oncol】中国多中心研究：HBV相关MCL的治疗模式、临床结局和基因突变, objectType=article, longId=824427, objectId=25d982442e29, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-doctor-review-PTX6YZP.jpg, objectUrl=/article/show_article.do?id=25d982442e29, replyNumber=0, likeNumber=69, createdTime=2024-05-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=25d982442e29, moduleTitle=【Hematol Oncol】中国多中心研究：HBV相关MCL的治疗模式、临床结局和基因突变, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25d982442e29)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2198390, encodeId=e00e2198390b7, content=<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一线治疗#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=c79411380f9' target=_blank style='color:#2F92EE;'>#MCL#</a>, objectTitle=【Blood】套细胞淋巴瘤一线治疗的现状和6个改善措施, objectType=article, longId=821416, objectId=1dfc8214160b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=1dfc8214160b, replyNumber=0, likeNumber=94, createdTime=2024-04-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1dfc8214160b, moduleTitle=【Blood】套细胞淋巴瘤一线治疗的现状和6个改善措施, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1dfc8214160b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2167013, encodeId=26cb216e013ad, content=<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>联合<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>治疗R/R <a href='/topic/show?id=c79411380f9' target=_blank style='color:#2F92EE;'>#MCL#</a>的2期TARMAC研究结果, objectTitle=【Blood】CAR-T联合伊布替尼治疗R/R MCL的2期TARMAC研究结果, objectType=article, longId=799477, objectId=d4d1e9947733, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=d4d1e9947733, replyNumber=0, likeNumber=81, createdTime=2023-11-06, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d4d1e9947733, moduleTitle=【Blood】CAR-T联合伊布替尼治疗R/R MCL的2期TARMAC研究结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d4d1e9947733)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2163006, encodeId=be06216300632, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>联合<a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a>治疗<a href='/topic/show?id=c79411380f9' target=_blank style='color:#2F92EE;'>#MCL#</a> , objectTitle=EClinicalMedicine：R/R MCL伊布替尼+硼替佐米后伊布替尼维持治疗的1/2期研究, objectType=article, longId=796080, objectId=c832e96080a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668017232524_4754896.png, objectUrl=/article/show_article.do?id=c832e96080a2, replyNumber=0, likeNumber=115, createdTime=2023-10-16, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c832e96080a2, moduleTitle=EClinicalMedicine：R/R MCL伊布替尼+硼替佐米后伊布替尼维持治疗的1/2期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c832e96080a2)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 风湿免疫小助手

MCL

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#诱导化疗# #自体干细胞移植# #伊布替尼# #MCL#

Nat. Rev. Clin. Oncol | 在一线治疗中添加伊布替尼可以改善符合移植资格的MCL患者的预后

2024-05-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#套细胞淋巴瘤# #MCL#

【Hematol Oncol】中国多中心研究：HBV相关MCL的治疗模式、临床结局和基因突变

2024-05-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#一线治疗# #套细胞淋巴瘤# #MCL#

【Blood】套细胞淋巴瘤一线治疗的现状和6个改善措施

2024-04-14发表于陕西省

(审核中...)

前往app查看评论内容

#CAR-T#联合#伊布替尼#治疗R/R #MCL#的2期TARMAC研究结果

【Blood】CAR-T联合伊布替尼治疗R/R MCL的2期TARMAC研究结果

2023-11-06发表于上海

(审核中...)

前往app查看评论内容

#伊布替尼#联合#硼替佐米#治疗#MCL#

EClinicalMedicine：R/R MCL伊布替尼+硼替佐米后伊布替尼维持治疗的1/2期研究

2023-10-16发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务